Download PDF
kleintier konkret 2018; 21(S 04): 2-8
DOI: 10.1055/a-0740-4069
Kardiologie
Georg Thieme Verlag KG Stuttgart · New York

Diagnose und Klassifizierung eines Patienten mit Mitralklappenerkrankung

Ralph Wendt
,
Jan-Gerd Kresken
,
Michael Deinert
Further Information

Publication History

Publication Date:
18 December 2018 (online)

Also available at
   Permissions and Reprints All articles of this category

Die chronisch degenerative Mitralklappenerkrankung (DMVD) ist die häufigste erworbene Herzerkrankung beim Hund. Dabei handelt es sich um eine chronische myxomatöse Degeneration der Mitralklappe, die eine Verdickung der Klappe und einen inkompletten Schluss der Klappensegel während der Systole verursacht. Die Folge ist eine Mitralklappenregurgitation.
 

  • Literatur

  • 1 Atkins CE, Keene BW, Brown WA. et al. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc 2007; 231 (07) 1061-1069
    CrossrefPubMedGoogle Scholar
  • 2 Atkins C, Bonagura J, Ettinger S. et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 3 (06) 1142-1150
    Google Scholar
  • 3 Bernay F, Bland JM, Haggström J. et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010; 24: 331-341
    CrossrefPubMedGoogle Scholar
  • 4 Borgarelli M, Savarino P, Crosara S. et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med 2008; 22 (01) 120-128
    CrossrefPubMedGoogle Scholar
  • 5 Boswood A, Häggström J, Gordon SG. et al. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial. J Vet Intern Med 2016; 30 (06) 1765-1779
    CrossrefPubMedGoogle Scholar
  • 6 Chetboul V, Serres F, Tissier R. et al. Association of Plasma N-Terminal Pro-B-Type Natriuretic Peptide Concentration with Mitral Regurgitation Severity and Outcome in Dogs with Asymptomatic Degenerative Mitral Valve Disease. J Vet Intern Med 2009; 23: 984-999
    CrossrefPubMedGoogle Scholar
  • 7 Cornell CC, Kittleson MD, Della Torre P. et al. Allometric scaling of M-mode cardiac measurements in normal adult dogs. J Vet Intern Med 2004; 18 (03) 311-321
    CrossrefPubMedGoogle Scholar
  • 8 Haggstrom J, Boswood A, OʼGrady M. et al. Effect of Pimobendan or Benazepril Hydrochloride on Survival Times in Dogs with Congestive Heart Failure Caused by Naturally Occurring Myxomatous Mitral Valve Disease: The QUEST Study. J Vet Intern Med 2008; 22 (05) 1124-1135
    CrossrefPubMedGoogle Scholar
  • 9 Kresken JG, Wendt R, Modler P. Praxis der Kardiologie Hund und Katze. Stuttgart: Enke; 2017
    Google Scholar
  • 10 Kvart C, Häggström J, Pedersen HD. et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002; 16 (01) 80-88
    CrossrefPubMedGoogle Scholar
  • 11 Ljungvall I, Rishniw M, Porciello F. et al. Murmur intensity in small-breed dogs with myxomatous mitral valve disease reflects disease severity. J Small Anim Pract 2014; 55 (11) 545-550
    CrossrefPubMedGoogle Scholar
  • 12 Lord PF, Hansson K, Carnabuci C. et al. Radiographic heart size and its rate of increase as tests for onset of congestive heart failure in Cavalier King Charles Spaniels with mitral valve regurgitation. J Vet Intern Med 2011; 25 (06) 1312-1319
    CrossrefPubMedGoogle Scholar
  • 13 Lord P, Hansson K, Kvart C, Häggström J. Rate of change of heart size before congestive heart failure in dogs with mitral regurgitation. J Small Anim Pract 2010; 51 (04) 210-218
    CrossrefPubMedGoogle Scholar
  • 14 Moonarmart W, Boswood A, Luis Fuentes V. et al. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract 2010; 51 (02) 84-96
    CrossrefPubMedGoogle Scholar
  • 15 OʼGrady MR, OʼSullivan ML, Minors SL, Horne R. Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman pinschers. J Vet Intern Med 2009; 23: 977-983
    CrossrefPubMedGoogle Scholar
  • 16 OʼGrady MR, Minors SL, OʼSullivan ML. et al. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. J Vet Intern Med 2008; 22 (04) 897-904
    CrossrefPubMedGoogle Scholar
  • 17 Oyama MA, Fox PR, Rush JE. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc 2008; 232: 1496-1503
    CrossrefPubMedGoogle Scholar
  • 18 Reynolds CA, Brown DC, Rush JE. et al. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: the PREDICT cohort study. J Vet Cardiol 2012; 14 (01) 193-202
    CrossrefPubMedGoogle Scholar
  • 19 Summerfield NJ, Boswood A, OʼGrady MR. et al. Efficacy of Pimobendan in the Prevention of Congestive Heart Failure or Sudden Death in Doberman Pinschers with Preclinical Dilated Cardiomyopathy (The PROTECT Study). J Vet Intern Med 2012; 26 (06) 1337-1349
    CrossrefPubMedGoogle Scholar